Measurable residual disease (MRD) is evaluated and analyzed in clinical trials, but less attention is currently given to it in practice, particularly in elderly patients, even those fit enough for transplant. Speaking from the 1st European Myeloma Network (EMN) Meeting, held in Turin, Italy, Elena Zamagni, MD, PhD, from the University of Bologna, Bologna, Italy, points out that although there are a number of difficulties involving combining imaging techniques to analyze MRD, it may help increase the success of treatment regimens and can help determine which course of treatment is best.
